

Quality ID #68 (NQF 0378): Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy
– National Quality Strategy Domain: Effective Clinical Care
– Meaningful Measure Area: Management of Chronic Conditions

2019 COLLECTION TYPE:
MIPS CLINICAL QUALITY MEASURES (CQMS)

MEASURE TYPE:
Process

DESCRIPTION:
Percentage of patients aged 18 years and older with a diagnosis of myelodysplastic syndrome (MDS) who are receiving erythropoietin therapy with documentation of iron stores within 60 days prior to initiating erythropoietin therapy

INSTRUCTIONS:
This measure is to be submitted a minimum of **once per performance period** for all myelodysplastic syndrome (MDS) patients seen during the performance period, regardless of when erythropoietin therapy is initiated; the quality action being measured is that iron stores were documented for each MDS patient receiving erythropoietin therapy within 60 days of starting erythropoietin therapy, regardless of how far back the erythropoietin therapy initiated. It is anticipated that Merit-based Incentive Payment System (MIPS) eligible clinicians who provide services for patients with the diagnosis of myelodysplastic syndromes will submit this measure.

Measure Submission Type:
Measure data may be submitted by individual MIPS eligible clinicians, groups, or third party intermediaries. The listed denominator criteria are used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality-data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.

DENOMINATOR:
All patients aged 18 years and older with a diagnosis of myelodysplastic syndrome (MDS) who are receiving erythropoietin therapy

DENOMINATOR NOTE: **Signifies that this CPT Category I code is a non-covered service under the Medicare Part B Physician Fee Schedule (PFS). These non-covered services should be counted in the denominator population for MIPS CQMs.*

Definition:
Erythropoietin Therapy – Includes the following medications: epoetin and darbepoetin for the purpose of this measure.

Denominator Criteria (Eligible Cases):
Patients aged ≥ 18 years on date of encounter

AND
Diagnosis for MDS (ICD-10-CM): D46.0, D46.1, D46.20, D46.21, D46.22, D46.4, D46.9, D46.A, D46.B, D46.C, D46.Z

AND
Patient encounter during the performance period (CPT): 99201, 99202, 99203, 99204, 99205, 99212,

99213, 99214, 99215, 99241*, 99242*, 99243*, 99244*, 99245*

WITHOUT

Telehealth Modifier: GQ, GT, 95, POS 02

AND

Patient receiving erythropoietin therapy: 4090F

NUMERATOR:

Patients with documentation of iron stores within 60 days prior to initiating erythropoietin therapy

NUMERATOR NOTE: Denominator Exception(s) are determined during the 60 days prior to initiating erythropoietin therapy.

Definition:

Documentation of Iron Stores – Includes either: 1) bone marrow examination including iron stain OR 2) serum iron measurement including ferritin, serum iron and total iron-binding capacity (TIBC).

Numerator Options:

<i>Performance Met:</i>	Documentation of iron stores prior to initiating erythropoietin therapy (3160F)
<u>OR</u>	
<i>Denominator Exception:</i>	Documentation of system reason(s) for not documenting iron stores prior to initiating erythropoietin therapy (3160F with 3P)
<u>OR</u>	
<i>Performance Not Met:</i>	Iron stores prior to initiating erythropoietin therapy not documented, reason not otherwise specified (3160F with 8P)

RATIONALE:

In comparison with supportive care alone, patients receiving EPO with or without granulocyte colony-stimulating factor plus supportive care had improved erythroid responses, similar survival, and incidence of acute myeloid leukemia transformation. Treatment of anemia in MDS with EPO plus G-CSF was associated with significantly improved survival outcome in patients with no or low transfusion need, while not affecting the risk of leukemic transformation. Erythropoiesis-stimulating agents (ESAs: erythropoietin-alfa, darbepoetin) are a key component of the strategy for improving anemia and reducing dependence on red blood cell (RBC) transfusions. Clinical trial results indicate that approximately 40% of selected patients have a clinically meaningful hemoglobin response to ESAs, with a median two-year response. To be effective, erythropoietin therapy requires that adequate iron stores be present due to iron's importance in red-blood-cell synthesis. By promoting the documentation of adequate iron stores in MDS patients requiring EPO therapy, the efficacy of the treatment will be enhanced.

CLINICAL RECOMMENDATION STATEMENTS:

The following clinical recommendation statements are quoted verbatim from the referenced clinical guidelines:

Anemia related to MDS commonly presents as a hypoproliferative macrocytic anemia, often associated with suboptimal elevation of sEpo levels. Bone marrow aspiration with iron stain, biopsy, and cytogenetics should be used to determine WHO subtype, iron status, and the level of ring sideroblasts. Patients should be considered for HLA-DR15 typing. Iron repletion needs to be verified before instituting Epo or darbepoetin therapy. (Category 2A Recommendation) (NCCN, 2018)

Baseline and periodic monitoring of iron, total iron-binding capacity, transferrin saturation, or ferritin levels and instituting iron repletion when indicated may help to reduce the need for ESAs, maximize symptomatic improvement for patients, and determine the reason for failure to respond adequately to ESA therapy. (ASH, 2010)

COPYRIGHT:

The Measure is not a clinical guideline, does not establish a standard of medical care, and has not been tested for all potential applications.

The Measure, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, eg, use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measure for commercial gain, or incorporation of the Measure into a product or service that is sold, licensed or distributed for commercial gain.

Commercial uses of the Measure require a license agreement between the user and the PCPI® Foundation (PCPI®) or American Society of Hematology (ASH). Neither ASH, nor the American Medical Association (AMA), nor the former AMA-convened Physician Consortium for Performance Improvement® (AMA-PCPI), nor PCPI, nor their members shall be responsible for any use of the Measure.

The AMA's and AMA-PCPI's significant past efforts and contributions to the development and updating of the Measure is acknowledged. ASH is solely responsible for the review and enhancement ("Maintenance") of the Measure as of August 15, 2014.

ASH encourages use of the Measure by other health care professionals, where appropriate.


THE MEASURE AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.

© 2018 PCPI® Foundation and American Society of Hematology. All Rights Reserved.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. ASH, the AMA, the PCPI and its members and former members of the AMA-PCPI disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

CPT® contained in the Measures specifications is copyright 2004-2018 American Medical Association. LOINC® copyright 2004-2018 Regenstrief Institute, Inc. SNOMED Clinical Terms® (SNOMED CT®) copyright 2004-2018 The International Health Terminology Standards Development Organisation. ICD-10 is copyright 2018 World Health Organization. All Rights Reserved.

**2019 Clinical Quality Measure Flow for Quality ID #68 NQF #0378:
Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients
Receiving Erythropoietin Therapy**



SAMPLE CALCULATIONS:

Data Completeness =

$$\frac{\text{Performance Met (a=40 patients)} + \text{Denominator Exception (b=10 patients)} + \text{Performance Not Met (c=20 patients)}}{\text{Eligible Population / Denominator (d=80 patients)}} = \frac{70 \text{ patients}}{80 \text{ patients}} = 87.50\%$$

Performance Rate =

$$\frac{\text{Performance Met (a=40 patients)}}{\text{Data Completeness Numerator (70 patients) - Denominator Exception (b=10 patients)}} = \frac{40 \text{ patients}}{60 \text{ patients}} = 66.67\%$$

*See the posted Measure Specification for specific coding and instructions to submit this measure.
 NOTE: Submission Frequency: Patient-Process

CPT only copyright 2018 American Medical Association. All rights reserved.
 The measure diagrams were developed by CMS as a supplemental resource to be used in conjunction with the measure specifications. They should not be used alone or as a substitution for the measure specification.

**2019 Clinical Quality Measure Flow Narrative for Quality ID #68 NQF #0378:
Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving
Erythropoietin Therapy**

Please refer to the specific section of the specification to identify the denominator and numerator information for use in submitting this Individual Specification.

1. Start with Denominator
2. Check Patient Age:
 - a. If the Patient Age is greater than or equal to 18 Years on Date of Encounter equals No during the measurement period, do not include in Eligible Population. Stop Processing.
 - b. If the Patient Age is greater than or equal to 18 Years on Date of Encounter equals Yes during the measurement period, proceed to check Patient Diagnosis.
3. Check Patient Diagnosis:
 - a. If Diagnosis for MDS as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
 - b. If Diagnosis for MDS as Listed in the Denominator equals Yes, proceed to check Encounter Performed.
4. Check Encounter Performed:
 - a. If Encounter Performed as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
 - b. If Encounter Performed as Listed in the Denominator equals Yes, proceed to check Telehealth Modifier.
5. Check Telehealth Modifier:
 - a. If Telehealth Modifier equals Yes, do not include in Eligible Population. Stop Processing.
 - b. If Telehealth Modifier equals No, proceed to check Receiving Erythropoietin Therapy.
6. Check Receiving Erythropoietin Therapy:
 - a. If Receiving Erythropoietin Therapy equals No, do not include in Eligible Population. Stop Processing.
 - b. If Receiving Erythropoietin Therapy equals Yes, include in the Eligible Population.
7. Denominator Population:
 - a. Denominator Population is all Eligible Patients in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 80 patients in the Sample Calculation.
8. Start Numerator
9. Check Documentation of Iron Stores Prior to Initiating Erythropoietin Therapy:
 - a. If Documentation of Iron Stores Prior to Initiating Erythropoietin Therapy equals Yes, include in Data Completeness Met and Performance Met.

- b. Data Completeness Met and Performance Met letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 40 patients in the Sample Calculation.
 - c. If Documentation of Iron Stores Prior to Initiating Erythropoietin Therapy equals No, proceed to check Documentation of System Reason(s) for Not Documenting Iron Stores Prior to Initiating Erythropoietin Therapy.
10. Check Documentation of System Reason(s) for Not Documenting Iron Stores Prior to Initiating Erythropoietin Therapy:
- a. If Documentation of System Reason(s) for Not Documenting Iron Stores Prior to Initiating Erythropoietin Therapy equals Yes, include in Data Completeness Met and Denominator Exception.
 - b. Data Completeness Met and Denominator Exception is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter b equals 10 patients in the Sample Calculation.
 - c. If Documentation of System Reason(s) for Not Documenting Iron Stores Prior to Initiating Erythropoietin Therapy equals No, proceed to check Iron Stores Prior to Initiating Erythropoietin Therapy Not Documented, Reason Not Otherwise Specified.
11. Check Iron Stores Prior to Initiating Erythropoietin Therapy Not Documented, Reason Not Otherwise Specified:
- a. If Iron Stores Prior to Initiating Erythropoietin Therapy Not Documented, Reason Not Otherwise Specified equals Yes, include in the Data Completeness Met and Performance Not Met.
 - b. Data Completeness Met and Performance Not Met letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter c equals 20 patients in the Sample Calculation.
 - c. If Iron Stores Prior to Initiating Erythropoietin Therapy Not Documented, Reason Not Otherwise Specified equals No, proceed to check Data Completeness Not Met.
12. Check Data Completeness Not Met :
- a. If Data Completeness Not Met, the Quality Data Code or equivalent was not submitted. 10 patients have been subtracted from the Data Completeness Numerator in the Sample Calculation.

SAMPLE CALCULATIONS:	
Data Completeness=	
Performance Met (a=40 patients) + Denominator Exception (b=10 patients) + Performance Not Met (c=20 patients) = 70 patients = 87.50%	
Eligible Population / Denominator (d=80 patients)	= 80 patients
Performance Rate=	
Performance Met (a=40 patients)	= 40 patients = 66.67%
Data Completeness Numerator (70 patients) – Denominator Exception (b=10 patients)	= 60 patients